These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 3785010)

  • 41. Acute myelofibrosis.
    Rupani M
    Am J Clin Pathol; 1982 Apr; 77(4):475-8. PubMed ID: 6951405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Mechanism of myelofibrosis in chronic myeloproliferative disorders].
    Nagao T; Yonekura S
    Rinsho Ketsueki; 1988 Jul; 29(7):983-8. PubMed ID: 2846914
    [No Abstract]   [Full Text] [Related]  

  • 43. [Uses of ultrastructural research in the study of thrombocythemias].
    Jean G; Marx R; Gautier A
    Nouv Rev Fr Hematol; 1966; 6(5):591-610. PubMed ID: 4226350
    [No Abstract]   [Full Text] [Related]  

  • 44. [So-called primary (idiopathic) osteomyelofibrosis/-sclerosis (OMF) within the scope of chronic myeloproliferative diseases. I. Initial clinical and histologic findings in 102 patients with special reference to early hyperplastic and advanced fibrosclerotic stages].
    Zankovich R; Thiele J; Mödder B; Steinberg T; Simon KG; Fischer R; Diehl V
    Med Klin (Munich); 1988 Oct; 83(19):617-28. PubMed ID: 3185420
    [No Abstract]   [Full Text] [Related]  

  • 45. [Histopathology of Ph1-negative chronic myeloproliferative diseases].
    Georgii A; Choritz H; Büsche G; Kreft A; Buhr T
    Pathologe; 1995 Jan; 16(1):62-9. PubMed ID: 7886016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Essential thrombocythemia that transformed to myelofibrosis after three years].
    Akimoto Y; Ishiyama T; Sano M; Ueno H; Nakamaki T; Hino K; Tomoyasu S; Tsuruoka N
    Rinsho Ketsueki; 1992 Apr; 33(4):520-4. PubMed ID: 1602618
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patho-anatomical features of the bone marrow.
    Lennert K; Nagai K; Schwarze EW
    Clin Haematol; 1975 Jun; 4(2):331-51. PubMed ID: 1102191
    [No Abstract]   [Full Text] [Related]  

  • 48. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
    Kvasnicka HM; Thiele J
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome.
    Pullarkat V; Bass RD; Gong JZ; Feinstein DI; Brynes RK
    Am J Hematol; 2003 Jan; 72(1):8-12. PubMed ID: 12508261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A case of Philadelphia-chromosome positive chronic idiopathic myelofibrosis.
    Chen F; Zhang C; Wang W; Li L; Yan S; Sun J; Zhang M; Ji C; Hou M
    Leuk Res; 2008 Apr; 32(4):665-7. PubMed ID: 17854891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Acute myelofibrosis--case reports of acute megakaryoblastic leukemia and acute myeloblastic leukemia].
    Ishibashi T; Uchida T; Matsuda S; Sato T; Kimura H; Shichishima T; Mita M; Suzuki A; Kariyone S
    Rinsho Ketsueki; 1985 Jul; 26(7):1145-50. PubMed ID: 3863978
    [No Abstract]   [Full Text] [Related]  

  • 52. Megakaryopoiesis in chronic myeloproliferative disorders: immunohistochemical evaluation of endoreduplicative activity by PCNA-staining reaction.
    Thiele J; Titius BR; Kvasnicka HM; Rechmeier W; Fischer R
    Anal Cell Pathol; 1994 Jul; 7(1):63-75. PubMed ID: 7981137
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanism of myelofibrosis in chronic myeloproliferative disorders.
    Yonekura S
    Tokai J Exp Clin Med; 1987 Sep; 12(3):141-5. PubMed ID: 3331217
    [No Abstract]   [Full Text] [Related]  

  • 54. Interactions between megakaryocytes and sinus wall. An ultrastructural study on bone marrow tissue in primary (essential) thrombocythemia.
    Thiele J; Galle R; Sander C; Fischer R
    J Submicrosc Cytol Pathol; 1991 Oct; 23(4):595-603. PubMed ID: 1764686
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings.
    Burkhardt R; Bartl R; Jäger K; Frisch B; Kettner G; Mahl G; Sund M
    J Clin Pathol; 1986 Mar; 39(3):237-52. PubMed ID: 3457024
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
    Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
    J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endogenous megakaryocyte colonies from peripheral blood in precursor cell cultures of patients with myeloproliferative disorders.
    Battegay EJ; Thomssen C; Nissen C; Gudat F; Speck B
    Eur J Haematol; 1989 Apr; 42(4):321-6. PubMed ID: 2656291
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Idiopathic myelofibrosis. Clinical aspects and studies on extracellular matrix metabolism.
    Hasselbalch HC
    Dan Med Bull; 1993 Mar; 40(1):39-55. PubMed ID: 8472598
    [No Abstract]   [Full Text] [Related]  

  • 59. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
    Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
    Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Myelofibrosis in myeloproliferative disorders.
    Srinivasan U; Talvalkar GV; Advani SH
    Indian J Cancer; 1978 Sep; 15(3):37-43. PubMed ID: 294411
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.